Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Cytos Provides Update of Phase 2b Clinical Trial of CYT003 in Allergic Asthma
Guidance for top-line results in 1H 2014 reiterated

SCHLIEREN, Switzerland, January 16, 2013 /PRNewswire/ --

Cytos Biotechnology Ltd (SIX:CYTN) today announced an update on the Phase 2b clinical trial with its lead product candidate, CYT003, in allergic asthma. The clinical trial will recruit approximately 360 adult patients with moderate to severe allergic asthma not sufficiently controlled on current standard therapy. The study will be conducted at more than 90 centers in North America and Europe, and is expected to read out top-line data in 1H 2014. Regulatory approvals to conduct the trial have been obtained in various countries in Europe and North America including the United States, where an IND (Investigational New Drug) application has been approved by the US Food & Drug Administration.

In the course of periodic drug quality measurements, a technical issue was identified with the rubber stoppers used to close the injection vials containing the clinical trial material. Cytos will replace this clinical trial material and have new material available at clinical trial sites in Q2 2013.

Overall guidance for the clinical trial remains unchanged. Cytos expects to have top-line data available in the course of 1H 2014 and full data towards the end of 2014.

Christian Itin, Chairman and CEO of Cytos Biotechnology, comments: "We appreciate the support of our investigators and are looking forward to evaluating CYT003 in patients with allergic asthma."

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a first-in-class biologic in Phase 2 clinical development as a potential new treatment for allergic asthma.

CYT003 acts via a novel, allergen-independent mechanism of action to selectively suppress the body's immune response to allergens, a predominant risk factor for asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function and asthma control in patients with persistent allergic asthma, even as standard inhaled corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in over 450 patients to date.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

http://www.cytos.com 

This foregoing press release may contain forward-looking statements that include words or phrases such as "are intended for", "are designed to", or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.

SOURCE Cytos

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
We are formally announcing the IoT Project Framework at @ThingsExpo Nov 4-6 in Santa Clara, CA. it will feature four overriding goals for the IoT in the year 2040: 1. To reduce poverty & disease 2. To eliminate violence as a way of settling disputes 3. To spur beneficial economic ...
I had a fun conversation with Mark Van Rijmenam (@VanRijmenam) a couple of weeks ago about cloud computing, Big Data, and the IoT. Mark runs BigData-Startups.com in Den Haag, Netherlands. We were mutually amused that he had chosen the name Think Bigger for his new book just as I had ch...
With Octoblu emerging from stealth mode, it seemed like a good idea to talk to a couple of key people there. We were able to do just that with company co-founders Geir Ramleth and Chris Matthieu. Geir Ramleth serves as CEO. He was named to CIO Magazine's Hall of Fame in 2008, and ser...
“Vote early and vote often.” Back in the 1920s and ’30s, when neither election technology nor oversight were as effective as they are today, and the likes of Al Capone were at work gaming the system, this phrase wasn’t a joke. It was a best practice. If you want guaranteed results, wh...
If you listen to the persistent murmur in the market surrounding the Internet of Things right now, you'd believe that it's all about sensors. Sensors and big data. Sensors that monitor everything from entertainment habits to health status to more mundane environmental data about your h...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE